DPX-Survivac

BIOLOGICAL9 trials

Sponsors

ImmunoVaccine Technologies, Inc. (IMV Inc.), University Health Network, Toronto, Sunnybrook Health Sciences Centre, Providence Health & Services

Conditions

Adult Diffuse Large Cell LymphomaAdult Refractory Diffuse Large B-Cell LymphomaAdvanced CancerBladder CancerBreast CancerDiffuse Large B-Cell LymphomaEpithelial Ovarian CancerFallopian Tube Cancer

Phase 1

Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer

CompletedNCT01416038

ImmunoVaccine Technologies, Inc. (IMV Inc.)Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer

Start: 2011-12-31End: 2013-05-31Updated: 2017-04-21

Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer

ImmunoVaccine Technologies, Inc. (IMV Inc.)Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Peritoneal Cancer

Start: 2016-04-30End: 2025-05-31Target: 85Updated: 2021-06-18

Phase 1b Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer

CompletedNCT03332576

ImmunoVaccine Technologies, Inc. (IMV Inc.)Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer

Start: 2013-08-23End: 2019-09-09Updated: 2021-06-18

Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer

Active, not recruitingNCT04895761

Providence Health & ServicesBreast Cancer

Start: 2021-09-10End: 2026-09-01Updated: 2025-03-10

Phase 2

A Study of DPX-Survivac Vaccine Therapy in Patients With Recurrent Survivin-expressing DLBCL

TerminatedNCT02323230

ImmunoVaccine Technologies, Inc. (IMV Inc.)Diffuse Large B-Cell Lymphoma

Start: 2015-01-31End: 2018-02-28Updated: 2021-06-22

Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Active, not recruitingNCT03029403

University Health Network, TorontoAdvanced Cancer, Fallopian Tube Cancer, Ovarian Cancer +1

Start: 2018-02-12End: 2026-04-12Updated: 2025-09-19

DPX-Survivac and Checkpoint Inhibitor in DLBCL

CompletedNCT03349450

Sunnybrook Health Sciences CentreAdult Diffuse Large Cell Lymphoma, Adult Refractory Diffuse Large B-Cell Lymphoma, Recurrent

Start: 2018-03-13End: 2023-07-18Updated: 2023-11-02

Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors

Active, not recruitingNCT03836352

ImmunoVaccine Technologies, Inc. (IMV Inc.)Bladder Cancer, Hepatocellular Carcinoma, Microsatellite Instability-High +2

Start: 2018-12-21End: 2023-12-31Target: 184Updated: 2022-03-31

DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

RecruitingNCT04920617

ImmunoVaccine Technologies, Inc. (IMV Inc.)Refractory Diffuse Large B-cell Lymphoma, Relapsed Diffuse Large B-cell Lymphoma

Start: 2021-06-18End: 2025-04-30Target: 102Updated: 2023-04-07

Related Papers

Characteristics of relapsed/refractory diffuse large B‐cell lymphoma patients with durable responses to maveropepimut‐S, pembrolizumab, and cyclophosphamide: Long‐term follow‐up from the SPiReL trial

eJHaem2024-12-122 citations

Abstract 2274: An immune-educating therapy, Maveropepimut-S, elicits a diverse and active anti-tumor T cell response in patients with advanced recurrent ovarian cancer

Cancer Research2023-04-04

Abstract OT2-20-01: Neoadjuvant survivin immunotherapy maveropepimut-S (MVP-S) to increase Th1 immune response in Ki67-high hormone receptor positive (HR+) early-stage breast cancer

Cancer Research2023-03-01

Vitalize Trial: A Phase 2b, Open-Label, Multicenter, Randomized Parallel-Group, Two-Stage, Study of the Novel Immunotherapeutic, Maveropepimut-S, and Pembrolizumab with and without Intermittent Low-Dose Cyclophosphamide, in Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Blood2022-11-15

913 Translational analysis of advanced metastatic bladder cancer patients treated with IO combination maveropepimut-S, cyclophosphamide, and pembrolizumab

Regular and Young Investigator Award Abstracts2022-11-01

646 Neoadjuvant immunotherapy combining maveropepimut-S (MVP-S) with letrozole decreases Ki67 and increases Th1 immune response in hormone receptor positive (HR+) early-stage breast cancer (ESBC)

Regular and Young Investigator Award Abstracts2022-11-01

Abstract 623: NK cells are involved in promoting anti-tumor responses to DPX-peptide immunotherapy

Cancer Research2022-06-15

Pembrolizumab, maveropepimut-S, and low-dose cyclophosphamide in advanced epithelial ovarian cancer: Results from phase 1 and expansion cohort of PESCO trial.

Journal of Clinical Oncology2022-06-018 citations

Neoadjuvant survivin-targeted immunotherapy maveropepimut-S (MVP-S) to increase Th1 immune response in Ki67-high hormone receptor-positive (HR+) early-stage breast cancer (ESBC).

Journal of Clinical Oncology2022-06-01

PB2138: VITALIZE TRIAL: A PHASE 2B, OPEN-LABEL, MULTICENTER, RANDOMIZED PARALLEL-GROUP, TWO-STAGE, STUDY OF MAVEROPEPIMUT-S, PEMBROLIZUMAB, WITH OR WITHOUT INTERMITTENT LOW-DOSE CYCLOPHOSPHAMIDE, IN R/R DLBLC

HemaSphere2022-06-01

Proteomic analysis of plasma exosomes as biomarkers of response to MVP-S based immunotherapy

The Journal of Immunology2022-05-01

353 Identification of potential response predictors to maveropepimut-S (DPX-Survivac), a novel T cell activating immunotherapy, in patients with advanced recurrent ovarian cancer

Regular and Young Investigator Award Abstracts2021-11-011 citations

356 Baseline PD-L1 expression and tumor immune infiltration is associated with clinical response in patients with r/r DLBCL treated with DPX-Survivac, low-dose cyclophosphamide and pembrolizumab

Regular and Young Investigator Award Abstracts2020-11-01

Infiltration of tumor by T cells following treatment with DPX-Survivac and intermittent low dose cyclophosphamide (CPA) leads to clinical responses in advanced recurrent ovarian cancer (OvCa).

Journal of Clinical Oncology2020-05-20

DPX-Survivac, a novel T-cell immunotherapy, to induce robust T-cell responses in advanced ovarian cancer.

Journal of Clinical Oncology2020-02-0412 citations

DPX-Survivac and intermittent low-dose cyclophosphamide (CPA) with or without epacadostat (E) in the treatment of subjects with advanced recurrent epithelial ovarian cancer (DeCidE<sup>1</sup> trial): T cell responses and tumor infiltration correlate with tumor regression.

Journal of Clinical Oncology2019-05-203 citations

New clinical data from the DeCidE1 trial: Results on DPX-Survivac, low dose cyclophosphamide (CPA), and epacadostat (INCB024360) in subjects with advanced recurrent epithelial ovarian cancer

Annals of Oncology2018-12-013 citations

Clinical data from the DeCidE<sup>1</sup> trial: Assessing the first combination of DPX-Survivac, low dose cyclophosphamide (CPA), and epacadostat (INCB024360) in subjects with stage IIc-IV recurrent epithelial ovarian cancer.

Journal of Clinical Oncology2018-05-209 citations

Bioanalysis of samples from advanced ovarian cancer subjects treated with a combination of DPX-Survivac, metronomic cyclophosphamide, and epacadostat: Preliminary data from the phase Ib DeCidE<sup>1</sup> Trial.

Journal of Clinical Oncology2018-05-20

A phase 2 clinical trial testing DPX-Survivac and metronomic low dose cyclophosphamide as immunotherapy for patients with recurrent diffuse large b-cell lymphoma.

Journal of Clinical Oncology2016-05-203 citations

3 more papers not shown